It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Patients with type 2 diabetes (T2D) are at risk for non-alcoholic fatty liver disease (NAFLD) and associated complications. This study evaluated the performance of international (EASL-EASD-EASO) and national (DGVS) guidelines for NAFLD risk stratification. Patients with T2D prospectively underwent ultrasound, liver stiffness measurement (LSM) and serum-based fibrosis markers. Guideline-based risk classification and referral rates for different screening approaches were compared and the diagnostic properties of simplified algorithms, genetic markers and a new NASH surrogate (FAST score) were evaluated. NAFLD risk was present in 184 of 204 screened patients (age 64.2 ± 10.7 years; BMI 32.6 ± 7.6 kg/m2). EASL-EASD-EASO recommended specialist referral for 60–77% depending on the fibrosis score used, only 6% were classified as low risk. The DGVS algorithm required LSM for 76%; 25% were referred for specialised care. The sensitivities of the diagnostic pathways were 47–96%. A simplified referral strategy revealed a sensitivity/specificity of 46/88% for fibrosis risk. Application of the FAST score reduced the referral rate to 35%. This study (a) underlines the high prevalence of fibrosis risk in T2D, (b) demonstrates very high referral rates for in-depth hepatological work-up, and (c) indicates that simpler referral algorithms may produce comparably good results and could facilitate NAFLD screening.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Leipzig University Medical Center, Division of Gastroenterology, Department of Medicine II, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, Integrated Research and Treatment Center (IFB) AdiposityDiseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
2 University of Leipzig, Integrated Research and Treatment Center (IFB) AdiposityDiseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, Clinical Trial Centre Leipzig, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
3 Leipzig University Medical Center, Division of Gastroenterology, Department of Medicine II, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
4 Leipzig University Medical Center, Division of Hepatology, Department of Medicine II, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
5 Leipzig University Medical Center, Division of Angiology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
6 University of Leipzig, Integrated Research and Treatment Center (IFB) AdiposityDiseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Leipzig University Medical Center, Division of Visceral, Transplantation, Thorax and Vascular Surgery, Section of Bariatric Surgery, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
7 Leipzig University Medical Center, Division of Endocrinology and Nephrology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
8 University of Leipzig, Integrated Research and Treatment Center (IFB) AdiposityDiseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); Leipzig University Medical Center, Division of Endocrinology and Nephrology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)